A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
2014
Clinical Cancer Research
Purpose: The CD52-targeted antibody alemtuzumab induces major clinical responses in a group of patients with myelodysplastic syndromes (MDS). The mechanism underlying this drug effect remains unknown. Experimental Design: We asked whether neoplastic stem cells (NSC) in patients with MDS (n ¼ 29) or acute myelogenous leukemia (AML; n ¼ 62) express CD52. Results: As assessed by flow cytometry, CD52 was found to be expressed on NSC-enriched CD34 þ /CD38 À cells in 8/11 patients with MDS and
doi:10.1158/1078-0432.ccr-13-2811
pmid:24799522
fatcat:2fqtdemyobgzhixzl2eupdjq7y